<p>The human glucose transporter GLUT1 is abundant in red blood cells, the blood-brain barrier and epithelial cells, where it mediates the transport of the energy metabolite, glucose. In the present work some properties of GLUT1, including affinity binding of both substrates and inhibitors, transport rates as well as permeabilities of aromatic amino acids and drug-membrane interactions were analyzed by chromatographic methods.</p><p>Reconstitution by size-exclusion chromatography on Superdex 75 from a detergent with a low CMC that provides monomeric GLUT1 was examined regarding D-glucose- and CB binding as well as D-glucose transport. Upon steric immobilization in Superdex 200 gel beads, residual detergent could be washed away and dissociation constants in the same range as reported for binding to GLUT1 reconstituted from other detergents were obtained. The transport rate into the GLUT1 proteoliposomes was low, probably due to residual detergent. Binding to GLUT1 at different pH was analyzed and the affinity of glucose and GLUT1 inhibitors was found to decrease with increasing pH (5–8.7). The average number of cytochalasin B-binding sites per GLUT1 monomers was, in most cases, approximately 0.4. GLUT1 may work as a functional monomer, dimer or oligomer. To determine whether GLUT1 was responsible for the transport of the aromatic amino acids tyrosine and tryptophan, uptake values and permeabilities of these amino acids into liposomes and GLUT1 proteoliposomes were compared to the permeabilities of D- and L- glucose in the same systems. Dihydrocytochalasin B was identified to be a new inhibitor of tyrosine and tryptophan transport into red blood cells. Ethanol turned out to inhibit the specific binding between CB and GLUT1 and also to decrease the partitioning of CB and drugs into lipid bilayers. A capacity factor for drug partitioning into membranes that allows comparison between columns with different amount of immobilized lipids was validated, and turned out to be independent of flow rate, amount of lipids and drug concentration in the ranges tested.</p>

The human glucose transporter GLUT1 is abundant in red blood cells, the blood-brain barrier and epithelial cells, where it mediates the transport of the energy metabolite, glucose. In the present work some properties of GLUT1, including affinity binding of both substrates and inhibitors, transport rates as well as permeabilities of aromatic amino acids and drug-membrane interactions were analyzed by chromatographic methods. Reconstitution by size-exclusion chromatography on Superdex 75 from a detergent with a low CMC that provides monomeric GLUT1 was examined regarding D-glucose- and CB binding as well as D-glucose transport. Upon steric immobilization in Superdex 200 gel beads, residual detergent could be washed away and dissociation constants in the same range as reported for binding to GLUT1 reconstituted from other detergents were obtained. The transport rate into the GLUT1 proteoliposomes was low, probably due to residual detergent. Binding to GLUT1 at different pH was analyzed and the affinity of glucose and GLUT1 inhibitors was found to decrease with increasing pH (5–8.7). The average number of cytochalasin B-binding sites per GLUT1 monomers was, in most cases, approximately 0.4. GLUT1 may work as a functional monomer, dimer or oligomer. To determine whether GLUT1 was responsible for the transport of the aromatic amino acids tyrosine and tryptophan, uptake values and permeabilities of these amino acids into liposomes and GLUT1 proteoliposomes were compared to the permeabilities of D- and L- glucose in the same systems. Dihydrocytochalasin B was identified to be a new inhibitor of tyrosine and tryptophan transport into red blood cells. Ethanol turned out to inhibit the specific binding between CB and GLUT1 and also to decrease the partitioning of CB and drugs into lipid bilayers. A capacity factor for drug partitioning into membranes that allows comparison between columns with different amount of immobilized lipids was validated, and turned out to be independent of flow rate, amount of lipids and drug concentration in the ranges tested.

Specific and non-specific interactions of solutes with immobilized biomembranes were studied using chromatographic methods. Liposomes, proteoliposomes and red blood cell (RBC) membrane vesicles were immobilized by a freeze-thawing procedure, whereas whole RBCs were adsorbed in the gel beds using electrostatic interaction, binding to wheat germ agglutinin (WGA) or the streptavidin-biotin interaction. Superporous agarose gel with coupled WGA was the most promising matrix for RBC adsorption and allowed frontal chromatographic analyses of the cells for about one week. Dissociation constants for the binding of cytochalasin B and glucose to the glucose transporter GLUT1 were determined under equilibrium conditions. The number of cytochalasin B-binding sites per GLUT1 monomer was calculated and compared to corresponding results measured on free and immobilized membrane vesicles and GLUT1 proteoliposomes. This allowed conclusions about the protein´s binding state in vitro and in vivo. Partitioning of drugs into biomembranes was quantified and the system was suggested as a screening method to test for possible intestinal absorption of drug candidates. We also studied how membrane partitioning of drugs is affected by the presence of integral membrane proteins or of charged phospholipids. An attempt to combine the theory for specific binding and membrane partitioning of solutes in a single equation is briefly presented.

Zahlreiche pathogene „missense“-Mutation, die verhindern, dass Proteine korrekt gefaltet werden, befinden sich in geordneten Regionen von Proteinen. Andere krankheitsrelevante Mutationen befinden sich in ungeordneten Regionen und beeinflussen somit nur begrenzt die Funktionalität, zum Beispiel durch Veränderungen kurzer linearer Sequenzmotive, die Protein-Protein Interaktionen vermitteln. In dieser Arbeit wird ein peptidbasierter Interaktionsscreen präsentiert mit dem sich Veränderungen im Interaktom identifizieren lassen. Synthetische Peptide von wild-typ und zugehörigen mutierten Proteinregionen ermöglichen die gleichzeitige Untersuchung von mehr als hundert Mutationen mittels Massenspektrometrie. Mehr als ein Drittel aller getesteten Mutationen hatten veränderte Interaktionen zur Folge. Darunter befanden sich auch drei Prolin zu Leucin Mutationen in zytosolischen Regionen von Transmembranproteinen, die zusammen mit dem benachbarten Leucin einem Dileucinmotiv ergeben und dadurch verstärkt mit Clathrin interagieren. Dieses Motiv wurde bereits mit Clathrin-vermittelter Endozytose in Verbindung gebracht. Die hinzugewonnene Endozytose könnte Krankheitsmechanismen erklären, da die Mislokalisation der betroffenen Transmembranproteine zum effektiven Verlust derer Funktion führen würde. Diese Hypothese wurde hier von verschiedenen in vitro und in vivo Experimenten bezüglich der P485L Mutation im Glukose Transporter-1 (GLUT1), die das GLUT1-Defizit-Syndrom hervorruft, bestätigt. Weitere Evidenz wurde außerdem für die Funktionalität anderer mutationsbedingter Dileucinmotive gewonnen. Die systematische Analyse von pathogenen Mutationen hat gezeigt, dass Dileucinmotive signifikant und spezifisch in ungeordneten zytosolischen Regionen von Transmembranproteinen überrepräsentiert sind. Dieser Peptidescreen macht das Potenzial unvoreingenommener Analysen zur Aufklärung von Krankheitsmechanismen deutlich, die von Veränderungen in Protein-Protein Interaktionen hervorgerufen werden. / Many disease-associated missense mutations prevent proteins from folding correctly and lead to loss-of-function. These mutations are often found in ordered regions of proteins. Another class of disease-related missense mutations can be found in disordered regions. These are thought to impair only specific parts of a protein’s functions. Those mutations could modify short linear motifs that mediate protein-protein interactions. Here, we designed a peptide-based interaction screen to identify interactions that are affected by mutations in disordered regions. We used synthetic peptides corresponding to the wild type and mutated protein regions spotted on cellulose membrane to pull-down interaction partners. This setup allows for the screening of more than hundred mutations at a time via mass spectrometry. Here, we focused on mutations implicated in neurological diseases. More than one-third of tested variant pairs show differential interactions. Three disease-related proline to leucine mutations in cytosolic tails of transmembrane proteins lead to gain of a dileucine sequence. Several dileucine-containing peptide motifs are involved in clathrin-mediated endocytosis (CME). Also in the presented screen, the newly created motifs mediate interaction with the CME machinery. This could explain the disease mechanisms since mislocalization of the affected transmembrane proteins would lead to their loss of function. This hypothesis has been corroborated for glucose transporter-1 (GLUT1) P485L, causing GLUT1 deficiency syndrome. We were able to provide functional evidence also for additional gained dileucine motifs. A systematic analysis of pathogenic mutations revealed dileucine motifs to be overrepresented in structurally disordered cytosolic regions of transmembrane proteins. The data gained with the peptide screen highlights the power of differential interactome mapping as a generic approach to unravel disease mechanisms caused by changes in protein-protein interactions.